Pharmaceuticals company Dr. Reddy's Laboratories announced Q3FY26 results Revenue: Q3FY26 came in at Rs 87,268, rising 4.4% YoY but easing 0.9% QoQ. Gross Margin: Q3FY26 gross margin was 53.6% (Rs 46,806), 510 bps lower YoY mainly due to lower Lenalidomide sales and an adverse mix. EBITDA: Quarterly EBITDA reached Rs 20,493 (23.5% of sales), down 11% YoY. Profit Before Tax (PBT): Q3FY26 PBT was Rs 15,429, translating to a 17.7% margin (-18% YoY; ?16% QoQ). Profit After Tax (PAT): Q3FY26 PAT was Rs 12,098, equal to 13.9% of revenue. Diluted Earnings per Share: Q3FY26 EPS: Rs 14.52 (not annualised). G V Prasad, Co-Chairman & Managing Director, said: “Our growth in Q3FY26 was supported by continued momentum in our branded businesses; aided by favourable forex, thus offsetting the impact of lower Lenalidomide sales. We continue to focus on disciplined execution of our strategic priorities of base business growth, pipeline advancement, operational efficiencies, and select inorganic opportunities, to create long-term value for our stakeholders.” Result PDF